

REMARKS

The Present Invention

The present invention pertains to isolated immunogenic peptides, compositions thereof, and methods of using the same.

The Pending Claims

Upon entry of this amendment, claims 100, 102, 103, 107-137, and 192-218 will be pending. Claims 100, 102, 103, 107-115, and 192-196 are directed to isolated immunogenic peptides, claims 116, 117, 197, and 198 are directed to compositions comprising the same, and claims 118-137 and 199-218 are directed to methods of using the compositions.

Amendments to the Claims

Claims 101 and 104-106 have been cancelled. Applicants reserve the right to pursue any canceled subject matter in a continuation, continuation-in-part, divisional, or other application. Cancellation of any subject matter should not be construed as abandonment of that subject matter.

Claim 100 has been amended to recite "consisting of a portion of SEQ ID NO: 39, wherein said portion comprises (i) at least 9 contiguous amino acids from amino acids 56-70 of SEQ ID NO: 39 or (ii) at least 9 contiguous amino acids from amino acids 448-462 of SEQ ID NO: 39". Claim 100 also has been amended to delete the phrase "or a derivative of either of the foregoing, wherein the amino acid sequence of the derivative is at least 85% identical with the immunogenic peptide." Furthermore, claim 100 has been amended to recite that the immunogenic peptide is about 9 to about 34 amino acids in length. The amendments of claim 100 are supported in the specification at, for example, page 8, lines 13-28, and page 9, lines 8-10. Claims 102 and 103 have been amended to recite "wherein the portion comprises" in order to be consistent with the amendments of claim 100. Claim 132 has also been amended to correct claim dependency. Claim 114 has been amended to delete extraneous punctuation (i.e., a comma). Claims 192-218 are new and are supported by the specification at, for example, page 9, lines 8-10, page 12, line 31 - page 13, line 11, page 44, line 27 - line 32, and Figures 6-12. Accordingly, no new matter has been added by way of these amendments.


Conclusion

The application is considered to be in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the

In re Appln. of Topalian et al.
Application No. 08/533,895

Examiner, a telephone conference would expedite the prosecution of the subject application,
the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



John Kilyk, Jr., Reg. No. 30,763
LEYDIG, VOIT & MAYER, LTD.
Two Prudential Plaza, Suite 4900
180 North Stetson
Chicago, Illinois 60601-6780
(312) 616-5600 (telephone)
(312) 616-5700 (facsimile)

Date: March 15, 2004

M:\Clients\NHT\amd 219490am3.doc